Clear leader
9 companies value 50 bn revenue 14 bn margin 6.7% free cash flow 1.3 bn avg. score 2.3
DXCM holds 64.7% of the group's value, 3.3x the runner-up
| Rank | Ticker | Company | Share | Value | Revenue | Margin | FCF | 5 years | FCF/px | Yield | What it does · why it is here |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DXCM | DexCom United States · score 6.8 | 65% | 32 bn | 5.0 bn | 20.1% | 1.4 bn | 4.3% | — | Continuous glucose monitors · Leader in continuous glucose monitoring alongside Abbott | |
| 2 | PODD | Insulet United States · score 5.5 | 20% | 9.8 bn | 3.0 bn | 12.3% | 0.3 bn | 3.0% | — | Omnipod tubeless insulin pump · Owner of Omnipod, the market-leading tubeless insulin pump | |
| 3 | MMED | MiniMed Group, Inc. United States · score 0.0 | 10% | 5.0 bn | 3.2 bn | -9.7% | -0.3 bn | -6.3% | — | Medical technology for diabetes management · California — revenue of $3.2bn | |
| 4 | TNDM | Tandem Diabetes Care United States · score 0.0 | 2% | 1.1 bn | 1.0 bn | -6.1% | -0.0 bn | -2.3% | — | Insulin pumps and diabetes technology · Insulin pumps integrated with continuous glucose sensors | |
| 5 | BBNX | Beta Bionics, Inc. United States · score 0.0 | 2% | 0.9 bn | 0.1 bn | -61.3% | -0.1 bn | -6.8% | — | Insulin pump with an adaptive closed-loop algorithm · California — revenue of $119m | |
| 6 | EMBC | Embecta Corp. United States · score 5.6 | 1% | 0.4 bn | 1.0 bn | 8.6% | 0.2 bn | 46.8% | 7.7% | Medical devices for people with diabetes · New Jersey — revenue of $1bn | |
| 7 | SENS | Senseonics Holdings, Inc. United States · score 0.0 | 1% | 0.4 bn | 0.1 bn | -225.3% | -0.1 bn | -22.9% | — | Long-term implantable glucose sensor · Maryland — revenue of $49m | |
| 8 | MODD | Modular Medical, Inc. United States · score 0.7 | — | — | — | — | -0.0 bn | — | — | Next-generation insulin pumps · California | |
| 9 | GCTK | Glucotrack, Inc. United States · score 1.8 | — | — | — | — | -0.0 bn | — | — | Implantable continuous glucose monitor · New Jersey |
Other industries in the same sector
- Sector overview
- Large-cap pharmaceuticals 9 companies
- Biotechnology 57 companies
- European pharmaceuticals 5 companies
- Lab tools and consumables 37 companies
- Health insurance and services 17 companies
- Medical devices 87 companies
- Specialty pharmaceuticals 77 companies
- Pharmaceutical distribution 7 companies
- Clinical-stage pharmaceuticals 251 companies
- Robotic surgery and advanced medtech 9 companies
- Hospitals 23 companies
- Emerging biotech 5 companies
and 22 industries more
- Molecular testing and advanced diagnostics 42 companies
- Vaccines and mRNA 14 companies
- Clinical-stage biotech 200 companies
- Generics and biosimilars 10 companies
- Animal health 7 companies
- Contract research (CRO) 10 companies
- Consumer health (OTC) 4 companies
- Healthcare software 18 companies
- Rehabilitation and home care 15 companies
- Genomics and sequencing 9 companies
- Structural heart 8 companies
- Ophthalmology 12 companies
- Medical imaging and hospital equipment 16 companies
- Diagnostic labs 6 companies
- Medical and dental supply distribution 3 companies
- Pharmaceutical royalties 5 companies
- Respiratory and sleep therapy 9 companies
- Orthopedic implants 17 companies
- Dialysis 3 companies
- Telehealth and digital health 12 companies
- Dental 4 companies
- Medical and recreational cannabis 16 companies
What this is. A catalogue, not a guide. Every industry with stocks listed on the NYSE or NASDAQ, the companies contending for its leadership, what each one does according to its own annual report, and the balance sheet it filed with the SEC.
The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.
The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.